Etrolizumab

Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7.^[1] Etrolizumab was developed by Genentech^[2][3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.^[4]

Etrolizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from rat)
Target	β7 subunit of α4β7 and αEβ7 integrin heterodimers
Clinical data
ATC code	none
Identifiers
CAS Number	1044758-60-2 N
IUPHAR/BPS	8407
ChemSpider	none
UNII	I2A72G2V3J
KEGG	D09901 N
Chemical and physical data
Formula	C6396H9874N1702O2010S42
Molar mass	144119.77 g·mol−1
NY (what is this?)  (verify)

As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.^[2][5][6] According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events.^[7]

Phase III clinical trials produced mixed results; and, on October 14, 2020, Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease,^[8] until disappointing trial results led to this being abandoned too in February 2022.^[9]